论文部分内容阅读
目的:探讨新辅助化疗(TAC方案)治疗局部晚期乳腺癌的临床疗效和毒副作用。方法:回顾性分析60例术前接受TAC新辅助化疗的局部晚期乳腺癌患者的临床资料。TAC方案:多西紫杉醇静脉滴注(75 mg·m-2,d 1);表阿霉素静脉滴注(75 mg·m-2,d 1);环磷酰胺静脉滴注(600 mg·m-2,d 1)。共进行为期4个疗程的治疗,1个疗程为21 d。结束后对患者化疗疗效以及毒副作用进行评定。结果:新辅助化疗(TAC方案)在LABC治疗中总有效率(cCR+cPR)为81.6%(49/60),其中临床完全缓解率(cCR)为18.3%(11/60),临床部分缓解率(cPR)为63.3%(38/60),病理完全缓解率(pCR)为10.0%(10/60)。主要的毒副反应以白细胞、中性白细胞减少为主,脱发和胃肠道反应,无败血症和死亡病例。结论:新辅助化疗(TAC方案)对局部晚期乳腺癌有较高缓解率和降期效果,安全性较好,毒性可控。
Objective: To investigate the clinical efficacy and side effects of neoadjuvant chemotherapy (TAC regimen) in the treatment of locally advanced breast cancer. Methods: The clinical data of 60 patients with locally advanced breast cancer who received TAC neoadjuvant chemotherapy before surgery were retrospectively analyzed. TAC regimen: docetaxel intravenous infusion (75 mg · m-2, d 1); epirubicin intravenous infusion (75 mg · m -2, d 1); cyclophosphamide intravenous infusion m-2, d 1). A total of 4 courses of treatment, a course of 21 days. After the end of the patient chemotherapy efficacy and side effects were assessed. Results: The total effective rate (cCR + cPR) of the new adjuvant chemotherapy (TAC regimen) was 81.6% (49/60) in LABC. The clinical complete response rate (CCR) was 18.3% (11/60) Rates (cPR) were 63.3% (38/60) and pathologic complete response rates (pCR) were 10.0% (10/60). The main toxic and side effects of leukocytes, neutropenia, hair loss and gastrointestinal reactions, no sepsis and deaths. Conclusion: The neoadjuvant chemotherapy (TAC regimen) has a higher response rate and down-time effect on locally advanced breast cancer with better safety and controllable toxicity.